| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-3262
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-328
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-332 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 |
| filingDate |
2019-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102288795-B1 |
| titleOfInvention |
Composition for treating or preventing metabolic syndrome comprising Protein phosphatase 1A |
| abstract |
The present invention relates to a composition for treating or preventing a metabolic disease comprising PPM1A (Protein phosphatase 1A) as an active ingredient, and more particularly, the PPM1A is obesity or diabetes by directly dephosphorylating the Ser273 residue of PPARĪ³. It can be very usefully used for the treatment or prevention of metabolic diseases, such as. |
| priorityDate |
2019-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |